Perrigo (PRGO) Change in Account Payables (2013 - 2026)
Perrigo's (PRGO) quarterly Change in Account Payables came in at -$35.9 million in Q1 2026, down 598.61% year-on-year from $7.2 million in Q1 2025, and down 915.91% on a QoQ basis from $4.4 million in Q4 2025.
Perrigo (PRGO) Change in Account Payables (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Change in Account Payables data on file, last reported at -$35.9 million in Q1 2026.
- On a quarterly basis, Change in Account Payables fell 598.61% year-over-year to -$35.9 million in Q1 2026; TTM through Mar 2026 was -$71.8 million, a 191.93% decrease from a year earlier, with the FY2025 full-year figure at -$28.7 million, down 152.95% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$35.9 million, down from $4.4 million in the prior quarter.
- Over the last five years, Change in Account Payables for PRGO reached as high as $72.6 million in Q2 2022 and fell as low as -$39.0 million in Q3 2023.
- Historically, Change in Account Payables has averaged $1.4 million across 5 years, with a median of -$13.2 million in 2025.
- Across the five-year window, Change in Account Payables soared 2068.0% in 2022 and tumbled 598.61% in 2026, its largest moves.
- Year by year, Change in Account Payables stood at $54.2 million in 2022, then slumped by 50.18% to $27.0 million in 2023, then surged by 118.89% to $59.1 million in 2024, then slumped by 92.55% to $4.4 million in 2025, then plunged by 915.91% to -$35.9 million in 2026.
- Per Business Quant data, the three most recent Change in Account Payables figures were -$35.9 million in Q1 2026, $4.4 million in Q4 2025, and -$13.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 30.60 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 32.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Perrigo | 1.40 Bn | 1.05 Bn | 325.50 Mn | -35.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | -35.90 Mn |
| Mar 28, 2026 | -35.90 Mn |
| Dec 31, 2025 | 4.40 Mn |
| Dec 31, 2025 | 4.40 Mn |
| Sep 27, 2025 | -13.20 Mn |
| Sep 27, 2025 | -13.20 Mn |
| Jun 28, 2025 | -27.10 Mn |
| Jun 28, 2025 | -27.10 Mn |
| Mar 29, 2025 | 7.20 Mn |
| Mar 29, 2025 | 7.20 Mn |
| Dec 31, 2024 | 59.10 Mn |
| Dec 31, 2024 | 59.10 Mn |
| Sep 28, 2024 | -18.80 Mn |
| Sep 28, 2024 | -18.80 Mn |
| Jun 29, 2024 | 30.60 Mn |
| Jun 29, 2024 | 30.60 Mn |
| Mar 30, 2024 | -16.70 Mn |
| Mar 30, 2024 | -16.70 Mn |
| Dec 31, 2023 | 27.00 Mn |
| Dec 31, 2023 | 27.00 Mn |